TY - CHAP

T1 - Validation of CASLI, Fibroscan-AST (FAST), and Agile3+ in a Russian Cohort of Patients with Metabolic Dysfunction-associated Steatotic Liver Disease

AU - Гомонова, Вероника Павловна

AU - Райхельсон, Карина Леонидовна

PY - 2025/9/17

Y1 - 2025/9/17

N2 - Introduction: The heterogeneous course of metabolic dysfunction-associated steatotic liver disease (MASLD)across different populations necessitates the assessment of new indices and their validation at the local level.Methods: We analyzed data from 43 patients who underwent transient elastography and had histologicallyconfirmed MASLD to validate the newly developed index for detecting compensated advanced chronic liver disease– Compensated Advanced Steatotic Liver diseases Index (CASLI), as well as the Fibroscan-AST (FAST) andAgile3+ scores.The CASLI index was calculated using the following formula:CASLI = 1 / (1 + e-z) × 100%z = -9,14 + 1,13×XT2DM + 1,77×XD + 0,05×XWCwhere: XT2DM – presence of type 2 diabetes mellitus (0 – absent, 1 – present), XD – presence of dyslipidemia (0 –absent, 1 – present), XWC – waist circumference (cm).The discriminatory ability of the models was assessed using the area under the receiver operating characteristiccurve (AUROC). Statistical significance was set at p<0.05.Results: The AUROC for CASLI was 0.87±0.06 (95% CI: 0.75–0.99, p = 0.004); for the FAST score (detectingNASH + NAS≥4 + F≥2), 0.83±0.06 (95% CI: 0.7–0.95, p<0.0001); and for Agile3+ (detecting advanced fibrosis,F≥3), 0.82±0.08 (95% CI: 0.67–0.98, p = 0.003). To improve diagnostic accuracy in the studied cohort, recalibratedthreshold values were determined: CASLI ≥0.2, FAST ≥0.52, Agile3+ ≥0.6.Conclusions: The evaluated predictive models demonstrated their diagnostic effectiveness in identifyingprogressive MASLD. CASLI showed the highest performance; however, threshold values require adjustment toenhance diagnostic accuracy.

AB - Introduction: The heterogeneous course of metabolic dysfunction-associated steatotic liver disease (MASLD)across different populations necessitates the assessment of new indices and their validation at the local level.Methods: We analyzed data from 43 patients who underwent transient elastography and had histologicallyconfirmed MASLD to validate the newly developed index for detecting compensated advanced chronic liver disease– Compensated Advanced Steatotic Liver diseases Index (CASLI), as well as the Fibroscan-AST (FAST) andAgile3+ scores.The CASLI index was calculated using the following formula:CASLI = 1 / (1 + e-z) × 100%z = -9,14 + 1,13×XT2DM + 1,77×XD + 0,05×XWCwhere: XT2DM – presence of type 2 diabetes mellitus (0 – absent, 1 – present), XD – presence of dyslipidemia (0 –absent, 1 – present), XWC – waist circumference (cm).The discriminatory ability of the models was assessed using the area under the receiver operating characteristiccurve (AUROC). Statistical significance was set at p<0.05.Results: The AUROC for CASLI was 0.87±0.06 (95% CI: 0.75–0.99, p = 0.004); for the FAST score (detectingNASH + NAS≥4 + F≥2), 0.83±0.06 (95% CI: 0.7–0.95, p<0.0001); and for Agile3+ (detecting advanced fibrosis,F≥3), 0.82±0.08 (95% CI: 0.67–0.98, p = 0.003). To improve diagnostic accuracy in the studied cohort, recalibratedthreshold values were determined: CASLI ≥0.2, FAST ≥0.52, Agile3+ ≥0.6.Conclusions: The evaluated predictive models demonstrated their diagnostic effectiveness in identifyingprogressive MASLD. CASLI showed the highest performance; however, threshold values require adjustment toenhance diagnostic accuracy.

KW - FAST

KW - Agile3+

KW - CASLI

KW - MAFLD

UR - https://www.apasl-stc2025tokyo.org/

M3 - Conference abstracts

SP - 218

BT - “New Horizons for Steatotic Liver Disease: Cutting Edge Research and Emerging Therapeutics

CY - Tokyo

T2 - New Horizons for Steatotic Liver Disease: Cutting Edge Research and Emerging Therapeutics

Y2 - 2 October 2025 through 3 October 2025

ER -